



Financial Results (Unaudited)
For Quarter Ended September 30, 2025

Q3 2025 Financial Results - Summary

Overview

- Revenue for the quarter ended as of 30 September 2025 on a like-for-like basis (excluding sub-scale lower-margin third-party product lines) was \$14.2m vs Q3, 2024 \$14.6m.
- The Company experienced significant quarter-on-quarter increase in revenue in Q3, 2025 following strong UniGold HIV sales combined with the resumption in manufacture and supply of its flagship rapid HIV test, TrinScreen HIV under its new offshored and outsourced manufacturing model in September.
- The Company achieved positive Adjusted EBITDA of \$0.5m for the quarter, reflecting progress as it continues to successfully deliver its Comprehensive Transformation Plan.

Net Loss & Loss per ADS

- Net loss of \$5.1m (Q3, 2024: \$4.8m).
- Basic and diluted loss per ADS: \$0.28 (Q3, 2024: \$0.46).
- Adjusted EBITDA in Q3, 2025 of \$0.5m (Q3, 2024: negative \$1.4m).

Q3 2025 Revenue & Gross Profit

Revenue Overview

- Total revenue: \$14.3m, compared to \$15.2m in Q3, 2024.
- Like-for-like revenue (excluding sub-scale lower-margin third-party product lines being discontinued): Q3, 2025: \$14.2m vs Q3, 2024 \$14.6m.
- Revenue movements in Q3'25 compared to Q3, 2024 were driven primarily by;
 - Trinscreen HIV sales of \$1.0m (Q3, 2024 \$2.4m) primarily reflecting the resumption in September of manufacture of its flagship rapid HIV test, TrinScreen HIV, underpinned by its World Health Organisation approval of its offshored and outsourced manufacturing.
 - Strong performance of our UniGold HIV sales with sales of \$2.6m (Q3, 2024: \$1.6m).
 - Recovery across our Haemoglobin products following transition to our new operating model.
- Main movements in revenues, on like-for-like basis, were:
 - Rapid HIV revenue (Q3, 2025: \$3.6m vs Q3, 2024: \$4.0m).
 - Haemoglobin revenue: (Q3, 2025: \$5.7m vs Q3, 2024: \$5.1m).

Gross Profit & Margin

- Gross margin: 45.2% (Q3, 2024: 35.0%): improved margins as sales were delivered under our revised operating model.
- Gross profit: \$6.5m (Q3, 2024: \$5.3m) with the improvement primarily driven by the increase in gross margin.

Q3 2025 Cost Base & Liquidity

- **R&D expense:** (Q3, 2025: \$0.8m vs Q3 2024: \$1.0m), with \$1.7m capitalised including \$1.0m for CGM programme.
- **SG&A expense:** (Q3, 2025: \$6.2m vs Q3, 2024: \$6.5m) with decrease driven primarily by cost reductions associated with the Comprehensive Transformation Plan partially offset by spend on non-recurring corporate finance activities.
- **Restructuring costs:** (Q3, 2025: \$0.3m vs Q3, 2024: \$0.3m).
- **Net Financing Expense:** \$4.3m in Q3, 2025 (Q3 2024: \$2.2m).
 - Fair value movement in respect of existing and new derivatives (Q3, 2025: expense of \$1.5m vs Q3, 2024: gain of \$0.8m).
 - Q3, 2025 includes a one-off non-cash modification gain of \$0.6m relating to the amendment of our term loan.

Liquidity & Cash Flow

- Cash balance at Q3, 2025 end: \$1.3m (Q3, 2024: \$2.8m).
 - Cash generated from operations in Q3, 2025: \$0.3m vs cash used in operations in Q3, 2024: \$3.6m.
 - Cash used in investing activities: Q3, 2025: \$1.5m vs Q3, 2024: \$3.1m, primarily comprising spend on intangible assets.
 - Financing activities: \$2.0m increase in senior secured loan, \$0.8m paid on finance lease liabilities.
- The Company obtained additional liquidity of approximately \$4.0m from its primary lender, Perceptive Advisors, in October 2025 through a combination of cash advance and payment-in-kind interest.

Net Financing Expense

(US\$'000's)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Amended Term Loan interest	3,635	3,224	10,327	8,841
Convertible note interest	309	292	914	863
Notional interest on lease liabilities for Right-of-use assets	158	152	479	449
Fair value movement on derivative balances	862	(845)	417	81
Fair value expense on new derivative balance	638	-	638	-
Capitalisation of borrowing costs	(769)	(601)	(2,174)	(1,424)
Non-cash modification gain to term loan	(564)	-	(1,706)	(3,567)
Reversal of cash interest payable on PPP loans	-	-	(228)	-
Other	16	14	49	38
Net Financing Expense	4,285	2,236	8,716	5,281

EBITDA & Adjusted EBITDA Reconciliation

(US\$'000's)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Loss for the period on continuing operations	(5,135)	(4,759)	(19,900)	(14,833)
Income tax expense/ (credit)	73	(35)	373	(99)
Net financing expense	4,285	2,236	8,716	5,281
Depreciation	306	260	919	359
Amortisation	354	338	1,036	1,082
Impairment and once off items	-	-	(158)	446
EBITDA	(117)	(1,960)	(9,014)	(7,746)
Share option expense	63	250	288	1,176
Corporate transaction related costs	319	-	477	-
Restructuring costs	269	339	2,728	2,278
Adjusted EBITDA	535	(1,371)	(5,521)	(4,310)

Use of Non-IFRS Financial Measures

The attached summary unaudited financial statements were prepared in accordance with International Financial Reporting Standards (IFRS). To supplement the consolidated financial statements presented in accordance with IFRS, the Company presents non-IFRS presentations of, EBITDA and Adjusted EBITDA. The adjustments to the Company's IFRS results are made with the intent of providing both management and investors a more complete understanding of the Company's underlying operational results, trends, and performance. Non-IFRS financial measures mainly exclude, if and when applicable, the effect of share-based payments, depreciation, amortization and impairment charges.

EBITDA and Adjusted EBITDA are presented to evaluate the Company's financial and operating results on a consistent basis from period to period. The Company also believes that these measures, when viewed in combination with the Company's financial results prepared in accordance with IFRS, provides useful information to investors to evaluate ongoing operating results and trends. EBITDA and Adjusted EBITDA, however, should not be considered as an alternative to operating income or net income for the period and may not be indicative of the historic operating results of the Company; nor is it meant to be predictive of potential future results. EBITDA and Adjusted EBITDA are not measures of financial performance under IFRS and may not be comparable to other similarly titled measures for other companies. Reconciliation between the Company's operating profit/(loss) and EBITDA and Adjusted EBITDA are presented.

Forward-Looking Statements

This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and of our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to reduce our debt and improve our capitalization, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties and risks related to condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2024 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech is a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. Our current products are used to detect a variety of health conditions including autoimmune, infectious and sexually transmitted diseases, and quantify the level of HbA1c in human blood. In January of 2024, we entered into the biosensor industry, with the acquisition of the biosensor assets of Waveform Technologies Inc. and we are currently developing a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide.

For further information, please see the Company's website: www.trinitybiotech.com

Trinity Biotech PLC

Consolidated Statement of Operations (unaudited) (US\$000's except share and per data)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Revenues	14,312	15,152	32,713	45,698
Cost of sales	(7,844)	(9,844)	(19,724)	(29,134)
Gross profit	6,468	5,308	12,989	16,564
Gross margin %	45.2%	35.0%	39.7%	36.2%
Other operating (expense)/income	30	-	30	42
Research & development expenses	(817)	(1,010)	(2,571)	(3,090)
Selling, general and administrative expenses	(6,190)	(6,517)	(18,889)	(20,443)
Selling, general and administrative expenses – Restructuring costs	(268)	(339)	(2,728)	(2,278)
Impairment charges and once off items	-	-	158	(446)
Operating Loss	(777)	(2,558)	(10,811)	(9,651)
Financial income	1	884	1	903
Financial expenses	(4,286)	(3,084)	(8,717)	(6,184)
Net financing expense	(4,285)	(2,236)	(8,716)	(5,281)
Loss before tax	(5,062)	(4,794)	(19,527)	(14,932)
Income tax credit/(expense)	(73)	35	(373)	99
Loss for the period on continuing operations	(5,135)	(4,759)	(19,900)	(14,833)
Loss for the period on discontinued operations	-	-	-	-
Loss for the period (all attributable to owners of the parent)	(5,135)	(4,759)	(19,900)	(14,833)
Basic Loss per ADS (US dollars)	(0.28)	(0.46)	(1.07)	(1.55)
Diluted loss per ADS (US dollars)	(0.28)	(0.46)	(1.07)	(1.55)
Weighted average no. of ADSs used in computing basic loss per ADS	18,655,853	10,387,099	18,530,293	9,577,871
Weighted average no. of ADSs used in computing diluted loss per ADS	18,655,853	10,387,099	18,530,293	9,577,871

Trinity Biotech PLC

Consolidated Balance Sheets (US\$000's)

	September 30, 2025 (unaudited)	June 30, 2025 (unaudited)	March 31, 2025 (unaudited)	December 31, 2024 (audited)
ASSETS				
Non-current assets				
Property, plant and equipment	4,011	4,309	4,382	4,621
Goodwill and intangible assets	57,813	55,919	53,656	51,343
Financial assets	2,764	2,763	2,553	2,455
Deferred tax assets	3,546	3,546	3,537	3,553
Derivative financial asset	35	67	115	166
Other assets	28	28	28	28
Total non-current assets	68,197	66,632	64,271	62,166
Current assets				
Inventories	19,158	20,129	20,271	19,374
Trade and other receivables	14,488	10,893	10,614	16,065
Income tax receivable	528	431	566	518
Cash, cash equivalents and deposits	1,341	1,546	4,066	5,167
Total current assets	35,515	32,999	35,517	41,124
TOTAL ASSETS	103,712	99,631	99,788	103,290
EQUITY AND LIABILITIES				
Equity attributable to the equity holders of the parent				
Share capital *	40	4,337	4,337	4,190
Share premium	63,845	63,797	63,797	63,397
Treasury shares	(24,922)	(24,922)	(24,922)	(24,922)
Accumulated deficit	(98,727)	(93,656)	(87,783)	(79,117)
Translation reserve	(5,998)	(5,826)	(5,786)	(5,461)
Equity component of convertible note	6,709	6,709	6,709	6,709
Other reserves	4,338	23	23	23
Total deficit	(54,715)	(49,538)	(43,625)	(35,181)

* Share capital reduced as a result of the reduction of the nominal value of each A Ordinary Share from US\$0.0109 to US\$0.0001 at the Company's Annual General Meeting on September 30, 2025, with the difference credited to 'Other Reserves'.

Trinity Biotech PLC

Consolidated Balance Sheets - continued
(US\$000's)

	September 30, 2025 (unaudited)	June 30, 2025 (unaudited)	March 31, 2025 (unaudited)	December 31, 2024 (audited)
EQUITY AND LIABILITIES - continued				
Current liabilities				
Income tax payable	487	472	390	364
Trade and other payables	30,355	26,486	25,287	26,782
Exchangeable senior note payable	210	210	210	210
Provisions	1,310	2,059	2,353	2,454
Lease liabilities	2,132	2,296	2,226	2,285
Total current liabilities	34,494	31,523	30,466	32,095
Non-current liabilities				
Senior secured term loan	88,686	83,643	79,607	72,391
Derivative financial liability	2,582	1,114	963	1,658
Convertible note	16,091	15,857	15,622	15,401
Contingent consideration	1,856	1,841	1,827	1,813
Provisions	75	75	75	75
Lease liabilities	10,084	10,554	10,305	10,477
Deferred tax liabilities	4,559	4,562	4,548	4,561
Total non-current liabilities	123,933	117,646	112,947	106,376
TOTAL LIABILITIES	158,427	149,169	143,413	138,471
TOTAL EQUITY AND LIABILITIES	103,712	99,631	99,788	103,290

Trinity Biotech PLC

Consolidated Statement of Cash Flows (unaudited)
(US\$000's)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Cash flows from operating activities				
Loss for the period	(5,135)	(4,759)	(19,900)	(14,833)
Adjustments to reconcile loss to cash used in operating activities:				
Depreciation	306	260	919	359
Amortisation	354	338	1,036	1,082
Income tax expense/(credit)	73	(35)	373	(99)
Financial income	(1)	(848)	(1)	(903)
Financial expense	4,286	3,084	8,717	6,184
Share-based payments	63	250	288	1,176
Foreign exchange losses/(gains) on operating cash flows	(232)	(107)	(1,238)	301
Impairment charges	-	-	28	446
Once off item	-	-	(186)	-
Other non-cash items	8	57	1,019	(149)
Operating cash flows before changes in working capital	(278)	(1,760)	(8,945)	(6,436)
Net movement on working capital	564	(1,880)	4,675	(2,349)
Cash used in operations	286	(3,640)	(4,270)	(8,785)
Income taxes (paid)/received	(150)	16	(184)	1,243
Net cash used in operating activities	136	(3,624)	(4,454)	(7,542)
Cash flows from investing activities				
Payments to acquire trades or businesses	-	(403)	-	(12,903)
Payments to acquire intangible assets	(1,464)	(2,589)	(5,320)	(7,080)
Payments to acquire financial assets	-	-	-	-
Acquisition of property, plant and equipment	(6)	(110)	(99)	(248)
Net cash used in investing activities	(1,470)	(3,102)	(5,419)	(20,231)

Trinity Biotech PLC

Consolidated Statement of Cash Flows (unaudited)
(US\$000's)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2025	2024	2025	2024
Cash flows from financing activities				
Issue of ordinary share capital including share premium (net of issuance costs)	-	7,117	547	6,847
Net proceeds from senior secured term loan	2,000	-	8,000	28,175
Interest paid	(77)	(2,195)	(231)	(6,180)
Payment of lease liabilities	(800)	(678)	(2,329)	(1,838)
Transaction costs paid in relation to the issue of share capital	-	-	-	-
Net cash generated by financing activities	1,123	4,244	5,987	27,004
Increase / (decrease) in cash and cash equivalents	(211)	(2,482)	(3,886)	(769)
Effects of exchange rate movements on cash held	5	5	60	(82)
Cash and cash equivalents at beginning of period	1,546	5,317	5,167	3,691
Cash and cash equivalents at end of period	1,341	2,840	1,341	2,840

The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).



Investor Queries

Trinity Biotech Plc

Paul Murphy

(353)-1-2769800

investorrelations@trinitybiotech.com

RedChip Companies Inc

David Gentry

(1)-407-644-4256

TRIB@redchip.com